Drug Financial Assistance Programme for Private Hospital Patients


Programme Introduction

Early Stage TNBC: KEYTRUDA is indicated for the treatment of patients with early-stage high-risk triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. Applicable to 200mg or 400mg dose of Pembrolizumab in each treatment cycle.

Each approved patient will receive a cash subsidy of HKD 13,600 per treatment cycle. Eligible participants are required to meet the following criteria:
1. holder of valid Hong Kong Identity Card; and
2. diagnosed as early-stage high-risk TNBC; and
3. referred by an accredited treating physician from public hospitals, private hospitals or clinics*; and
4. under the treatment of immunotherapy drug Pembrolizumab of 200 mg or 400 mg per cycle.


*patients referred by private sector shall pass financial assessment (personal income of recent 12-month average is less than HKD 60,000 per month).


For further information, please refer to “Financial Assistance Programme Leaflet (Chinese only)”.

Doctor's Recommendation (Click here to download)

Infusion Acknowledgement form (Click here to download)


For more details, please refer to Chinese Page